BCAL Diagnostics (ASX:BDX) Interest Expense: A$-0.10 Mil (TTM As of Dec. 2025)


What is BCAL Diagnostics Interest Expense?

BCAL Diagnostics ASX:BDX +4.17% Interest Expense is A$-0.10 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BCAL Diagnostics's interest expense for the six months ended in Dec. 2025 was A$ -0.11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BCAL Diagnostics's Operating Income for the six months ended in Dec. 2025 was A$ -5.02 Mil. BCAL Diagnostics's Interest Expense for the six months ended in Dec. 2025 was A$ -0.11 Mil. BCAL Diagnostics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BCAL Diagnostics  (ASX:BDX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BCAL Diagnostics's Interest Expense for the six months ended in Dec. 2025 was A$-0.11 Mil. Its Operating Income for the six months ended in Dec. 2025 was A$-5.02 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was A$2.98 Mil.

BCAL Diagnostics's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

BCAL Diagnostics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

BCAL Diagnostics Interest Expense Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Interest Expense Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Interest Expense
0.00 -0.02 -0.04 -0.05

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 0.01 -0.05 0.00 -0.11

BCAL Diagnostics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of A$-0.10 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Interest Expense of A$-0.10 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Interest Expense too high?
BCAL Diagnostics' current Interest Expense is A$-0.10 Mil.
How does BCAL Diagnostics' Interest Expense compare to TMO and DHR?
BCAL Diagnostics' Interest Expense of A$-0.10 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Diagnostics & Research company?
A good Interest Expense depends on the Medical Diagnostics & Research industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Interest Expense is A$-0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Interest Expense of A$-0.10 Mil. The current Interest Expense is A$-0.10 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Interest Expense is A$-0.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.